★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Roche Holding AG (ROP) Moat Analysis
Roche Holding AG
ROP · SIX Swiss Exchange (participation certificate)
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Roche generated CHF 30.364 billion of H1 2026 sales, up 6% at constant exchange rates but down 2% in Swiss francs, and CHF 9.671 billion of IFRS operating profit. Pharmaceuticals contributed 77.8% of sales and 92.6% of the two profitable divisions. Its moat is product-specific patent and regulatory exclusivity: the five top growth medicines generated CHF 11.0 billion, while five expired-patent products generated CHF 2.6 billion and declined 8% at constant rates. Diagnostics has the more systemic moat. Its large cobas installed base supports recurring assay demand, while integrated reagents, automation, and digital workflows create switching friction. China pricing reforms and tendering constrain that advantage. Patent expiry, pipeline failures, payer pressure, China reforms, and diagnostic platform competition are the main risks.
Primary segment
Pharmaceuticals
Market structure
Competitive
Market share
—
HHI: —
Coverage
2 segments · 8 tags
Updated 2026-08-23
Segments
Pharmaceuticals
Innovative (branded) prescription pharmaceuticals
Revenue
77.8%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Diagnostics
In vitro diagnostics platforms, assays and digital laboratory workflow solutions
Revenue
22.2%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Pharmaceuticals
Innovative (branded) prescription pharmaceuticals
H1 2026 sales were CHF 23,629m, or 77.8191279% of Group sales, up 6% at CER and down 1% in CHF. IFRS operating profit was CHF 10,838m; the 92.5691835% operating-profit share is normalized across the two positive divisions and excludes the CHF 2,037m Corporate loss.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivities protect individual medicines, not the division indefinitely; H1 erosion in expired-patent products demonstrates the cliff.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Loss of exclusivity (patent cliffs) on major products
- Biosimilar/generic substitution and tendering
- Government price controls and reference pricing
Leading indicators
- Revenue concentration in products within ~3 years of LOE
- Biosimilar penetration rates for key molecules
- Net price realization trends (gross-to-net, price cuts)
Counterarguments
- The IP moat is temporary at the molecule level; competitors can leapfrog with better efficacy/safety
- Payers can reduce pricing power even before LOE via rebates, formularies and reference pricing
Diagnostics
In vitro diagnostics platforms, assays and digital laboratory workflow solutions
H1 2026 sales were CHF 6,735m, or 22.1808721% of Group sales, up 3% at CER and down 3% in CHF. IFRS operating profit was CHF 870m; the 7.4308165% operating-profit share is normalized across the two positive divisions. China pricing reforms drove Asia-Pacific sales down 5% at CER. PathAI was agreed but not completed and is excluded from current moat evidence.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Large installed instrument base drives recurring assay/test volume (pull-through), supporting repeatable consumables revenue and customer stickiness.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Price pressure via tenders and hospital procurement cycles
- Customers adopting multi-vendor strategies to reduce dependence
- Technology shifts that reduce demand for central lab testing
Leading indicators
- Analytical units placed (cobas pro/pure) and active installed base
- Test volumes and assay menu expansion on installed platforms
- Customer retention/renewal outcomes at contract refresh
Counterarguments
- Large labs can switch platforms at refresh if switching costs are outweighed by price/performance gains
- Some assays are commoditised and can be sourced competitively despite platform lock-in
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Integration of instruments, automation and digital analytics into lab operations increases workflow switching costs and supports share retention.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Third-party middleware/LIS interoperability reduces vendor lock-in
- Open standards and competitor integrations improve portability
- IT/security incidents undermine trust in digital workflow products
Leading indicators
- Adoption of digital solutions (e.g., navify) among installed base customers
- Interoperability requirements (regulatory or customer-driven)
- Share losses/wins in large reference-lab tenders
Counterarguments
- Many labs already operate with independent LIS/middleware; vendor software may be optional
- Integration value may be competed away if rivals offer similar end-to-end workflows
Evidence
Sales of products with expired patents ... were CHF 2.6 billion, a decrease of 8% at CER
Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra continued to erode after exclusivity expired.
Sales of products with expired patents ... decreased by a combined CHF 0.7 billion
Confirms ongoing competitive pressure from biosimilars/generics once protected products face entry.
Analytical units placed in the cobas pro line 6,700+
Installed analytical units underpin pull-through economics for assays, reagents and workflow services.
Roche Diagnostics tests delivered to our customers 31 billion
Indicates very large ongoing test volumes consistent with consumables-heavy recurring revenue.
A new assay expands the menu and consumables pull-through available to the existing cobas installed base.
Showing 5 of 7 sources.
Risks & Indicators
Erosion risks
- Loss of exclusivity (patent cliffs) on major products
- Biosimilar/generic substitution and tendering
- Government price controls and reference pricing
- Pipeline clinical failures or safety signals
- Price pressure via tenders and hospital procurement cycles
- Customers adopting multi-vendor strategies to reduce dependence
Leading indicators
- Revenue concentration in products within ~3 years of LOE
- Biosimilar penetration rates for key molecules
- Net price realization trends (gross-to-net, price cuts)
- Late-stage pipeline readouts and approval cadence
- Analytical units placed (cobas pro/pure) and active installed base
- Test volumes and assay menu expansion on installed platforms
Research ROP elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.